Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jingwu Road, Huaiyin District, Jinan, 250012, Shandong, China.
Department of Nuclear Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210018, China.
Abdom Radiol (NY). 2022 Jan;47(1):297-309. doi: 10.1007/s00261-021-03293-4. Epub 2021 Oct 13.
To investigate and validate the prognostic value of nomogram models for predicting disease-free survival (DFS) and overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC).
In this retrospective study, 223 patients (age 54.38 ± 10.93 years) with pathologically confirmed ccRCC who underwent resection and lymph node dissection between March 2010 and September 2018 were investigated. All patients were randomly divided into training (n = 155) and validation (n = 68) cohorts. Radiomics features were extracted from computed tomography (CT) images in the unenhanced, corticomedullary, and nephrographic phases. Radiomic score was calculated and combined with clinicopathological factors for model construction and nomogram development. Clinicopathological factors and imaging features were collected at initial diagnosis. Univariate and multivariate Cox proportional hazards regression analyses were used to evaluate the relationship between the radiomics signature and prognosis outcomes.
There were four prognostic factors for predicting DFS and five factors for predicting OS in our nomogram model (P < 0.05). The radiomics signature correlated independently with DFS (hazard ratio = 27; P < 0.001) and OS (hazard ratio = 25; P < 0.001). The nomogram showed excellent performance (C-index = 0.825) for predicting DFS. The combined nomogram also showed the highest C-index for OS (C-index = 0.943), which was verified in the validation dataset.
The combined nomogram model based on radiomics, clinicopathological factors, and preoperative CT features can accurately perform prognosis and survival analysis and can potentially be used for preoperative non-invasive survival prediction in ccRCC patients.
研究并验证列线图模型预测肾透明细胞癌(ccRCC)患者无病生存(DFS)和总生存(OS)的预后价值。
本回顾性研究纳入了 2010 年 3 月至 2018 年 9 月接受切除术和淋巴结清扫术的 223 例病理证实为 ccRCC 的患者(年龄 54.38±10.93 岁)。所有患者均随机分为训练集(n=155)和验证集(n=68)。从增强、皮质髓质和肾实质期的 CT 图像中提取放射组学特征。计算放射组学评分,并结合临床病理因素构建模型和列线图。在初始诊断时收集临床病理因素和影像学特征。采用单因素和多因素 Cox 比例风险回归分析评估放射组学特征与预后结果之间的关系。
我们的列线图模型有四个预测 DFS 的预后因素和五个预测 OS 的因素(P<0.05)。放射组学特征与 DFS(风险比=27;P<0.001)和 OS(风险比=25;P<0.001)独立相关。该列线图在预测 DFS 方面表现出优异的性能(C 指数=0.825)。联合列线图在预测 OS 方面也显示出最高的 C 指数(C 指数=0.943),并在验证数据集中得到验证。
基于放射组学、临床病理因素和术前 CT 特征的联合列线图模型可以准确进行预后和生存分析,有可能用于术前无创预测 ccRCC 患者的生存情况。